SETDB1 and neoplasm: In mouse tumor models, loss of SETDB1 results in expression of ERV sequences, which induce ERV-derived type I IFN responses, which associates with enhanced lymphocyte infiltration, reduced tumor growth, and enhanced responsiveness to radiotherapy (37, 38).